EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals (NASDAQ:ADIL) has begun dosing patients in a pharmacokinetics study of AD04 for Alcohol Use Disorder. The study aims to optimize the design for a Phase 3 clinical trial and meet FDA requirements. Results are expected in early Q4 2024.
June 05, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals has started dosing patients in a pharmacokinetics study of AD04 for Alcohol Use Disorder. The study aims to optimize the design for a Phase 3 clinical trial and meet FDA requirements. Results are expected in early Q4 2024.
The initiation of the pharmacokinetics study is a significant step towards the Phase 3 clinical trial and FDA approval. Positive results could lead to a substantial increase in stock price due to the potential market for AD04.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100